When was 4D Pharma founded?

4D Pharma was founded in 2008 and raised its 1st funding round 6 years after it was founded.

Where is 4D Pharma located?

4D Pharma is headquartered in Leeds, United Kingdom.

Who is the current CEO of 4D Pharma?

Duncan Peyton of 4D Pharma. They have also founded 1 company.

How many employees does 4D Pharma have?

As of Mar 01, 2026, the latest employee count at 4D Pharma is 50 - 199.

Is 4D Pharma a funded company?

4D Pharma is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 2014.

When was the latest funding round of 4D Pharma?

4D Pharma's latest funding was a $***** Post IPO round on Mar 17, 2021, with participation from 0 investor. Its primary sector is Microbiome Therapeutics. In United Kingdom, the Microbiome Therapeutics sector has seen $30.3M in funding in 2026 to date.

Where does 4D Pharma rank among its competitors?

4D Pharma ranks 295th amongst 1941 active competitors, of which 113 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of 4D Pharma?

4D Pharma's top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

4D Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

4D Pharma is a late stage company based in Leeds (United Kingdom), founded in 2008 by Duncan Peyton. It operates as a Developer of drugs from gut bacteria for multiple diseases. 4D Pharma has raised an undisclosed amount in funding. The company has 1941 active competitors, including 113 funded and 215 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.

Company Details

Developer of drugs from gut bacteria for multiple diseases. The company leverages a MicroRx platform, for developing live biotherapeutic products for a large number of diseases including cancer, gastrointestinal disease, respiratory disease, and conditions of the central nervous system (CNS).

Website: www.4dpharmaplc.com/
Social
Email ID: *****@4dpharmaplc.com

Key Metrics

Founded Year

2008

Location

Leeds, United Kingdom

Stage

Late Stage

Latest Funding Round

Post IPO, Mar 17, 2021, $*****

Investors

Aquarius Equity Partners

Ranked

295^th among 1941 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Investment & Acquisitions

BIOMAR & 1 more

Similar Companies

Novozymes & 90 more

View 4D Pharma's full profile

4D Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
4d Pharma Plc CIN: 8840579 , United Kingdom, Active	Jan 09, 2014	-	106 (As on Dec 31, 2021)

4D Pharma has raised funding over 7 rounds. Its first funding round was on Feb 2014. 4D Pharma has 1 institutional investor.

Here is the list of recent funding rounds of 4D Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 17, 2021	6760438	Post IPO	3040343	8767568	9978000	2776975
Jul 13, 2020	3968820	Post IPO	7127031	7242380	9226786	1961871
Feb 18, 2020	9201448	Post IPO	7915090	8470114	3113722	2675577

Access funding benchmarks and valuations. Sign up today!

View details of 4D Pharma's funding rounds and investors

The founders of 4D Pharma is Duncan Peyton. Duncan Peyton is the CEO of 4D Pharma.

Here are the details of 4D Pharma's key team members:

Duncan Peyton: Co-Founder & CEO of 4D Pharma.

View details of 4D Pharma's Founder profiles and Board Members

4D Pharma's employee count trend

4D Pharma has 50 - 199 employees as of Mar 26. Here is 4D Pharma's employee count trend over the years:

Uncover 4D Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 4D Pharma include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of 4D Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, CHV & 3 others	73/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
9th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
295th	4D Pharma 2008, Leeds (United Kingdom), Late Stage	Developer of drugs from gut bacteria for multiple diseases	-	Aquarius Equity Partners	30/100